Literature DB >> 23237237

Monascin and ankaflavin have more anti-atherosclerosis effect and less side effect involving increasing creatinine phosphokinase activity than monacolin K under the same dosages.

Chun-Lin Lee1, Yu-Ping Hung, Ya-Wen Hsu, Tzu-Ming Pan.   

Abstract

Monacolin K has long been considered a major effective component in the hypolipidemic functions of Monascus . Monacolin K also serves as a well-known hypolipidemic medication, but its side effect myopathy is a concern. Monascin and ankaflavin, the yellow pigments produced by Monascus species, have been proven to possess hypolipidemic functions; however, no studies have compared the hypolipidemic effects of monascin, ankaflavin, and monacolin K under the same dosages. In this study, the equal dosages of monascin, ankaflavin, and monacolin K were oral administrated to hamsters fed a high cholesterol diet for 6 weeks. Comparison of the displayed hypolipidemic and anti-atherosclerosis effects was performed, in addition to an investigation into the inducement of side effect. The results indicated that monascin and ankaflavin were similar to monacolin K in significantly reducing total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels in serum and lipid plaque (p < 0.05) in the heart aorta. In addition, ankaflavin achieved the effects of serum TC and TG reduction, with no significant difference as compared to those effects of monacolin K (p > 0.05). However, as compared to monacolin K, ankaflavin possessed more significant effects on the prevention of fatty liver and lipid plaque accumulation in heart aorta. More importantly, monascin significantly enhanced high-density lipoprotein cholesterol (HDL-C) concentrations, while monacolin K displayed the opposite effect. Regarding the side effect, monacolin K also raised elevated creatinine phosphokinase (CPK) activity, which was highly correlated with rhabdomyolysis development, while monascin and ankaflavin did not induce such a side effect. In conclusion, MS and AK had the potential to be developed as hypolipidemic agents without rhabdomyolysis development.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23237237     DOI: 10.1021/jf304346r

Source DB:  PubMed          Journal:  J Agric Food Chem        ISSN: 0021-8561            Impact factor:   5.279


  7 in total

Review 1.  Haematoma scavenging in intracerebral haemorrhage: from mechanisms to the clinic.

Authors:  Gaiqing Wang; Li Wang; Xin-Gang Sun; Jiping Tang
Journal:  J Cell Mol Med       Date:  2017-12-26       Impact factor: 5.310

2.  Effect of initial pH, different nitrogen sources, and cultivation time on the production of yellow or orange Monascus purpureus pigments and the mycotoxin citrinin.

Authors:  Matej Patrovsky; Kristyna Sinovska; Barbora Branska; Petra Patakova
Journal:  Food Sci Nutr       Date:  2019-09-27       Impact factor: 2.863

3.  Monascin and Ankaflavin of Monascus purpureus Prevent Alcoholic Liver Disease through Regulating AMPK-Mediated Lipid Metabolism and Enhancing Both Anti-Inflammatory and Anti-Oxidative Systems.

Authors:  Jhao-Ru Lai; Ya-Wen Hsu; Tzu-Ming Pan; Chun-Lin Lee
Journal:  Molecules       Date:  2021-10-18       Impact factor: 4.411

4.  Comparative transcriptomic analysis reveals the regulatory effects of inorganic nitrogen on the biosynthesis of Monascus pigments and citrinin.

Authors:  Jia-Li Hong; Li Wu; Jin-Qiang Lu; Wen-Bin Zhou; Ying-Jia Cao; Wen-Long Lv; Bin Liu; Ping-Fan Rao; Li Ni; Xu-Cong Lv
Journal:  RSC Adv       Date:  2020-02-03       Impact factor: 4.036

5.  An Ethnopharmaceutical Study on the Hypolipidemic Formulae in Taiwan Issued by Traditional Chinese Medicine Pharmacies.

Authors:  Min-Han Chi; Jung Chao; Chien-Yu Ko; Shyh-Shyun Huang
Journal:  Front Pharmacol       Date:  2022-09-15       Impact factor: 5.988

Review 6.  Fungal Pigments and Their Roles Associated with Human Health.

Authors:  Lan Lin; Jianping Xu
Journal:  J Fungi (Basel)       Date:  2020-11-12

7.  A randomized, double-blind clinical study of the effects of Ankascin 568 plus on blood lipid regulation.

Authors:  Sheng-Fu Liu; Yin-Ruei Wang; You-Cheng Shen; Chien-Li Chen; Chine-Ning Huang; Tzu-Ming Pan; Chin-Kun Wang
Journal:  J Food Drug Anal       Date:  2017-06-01       Impact factor: 6.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.